20 September 2020: Lab/In Vitro Research
The Clinical Role of Preoperative Serum CA19-9 and Carcinoembryonic Antigen (CEA) Levels in Evaluating the Resectability of Advanced Gallbladder Cancer
Wencong Ma BCF* , Wei Li DE* , Jinghan Wang DF* , Rui Wu BC , Chen Liu D , Feiling Feng AF* , Xiaoqing Jiang AEF*DOI: 10.12659/MSM.925017
Med Sci Monit 2020; 26:e925017
Table 1 Baseline characteristics of patients with gallbladder cancer.
| Total | R0 | R1/R2 | Unresected | P value | |
|---|---|---|---|---|---|
| No. patients | 309 | 169 | 121 | 19 | |
| Age. Yr, mean±SD | 59.99±8.66 | 59.95±7.61 | 60.97±9.86 | 54.12±7.24 | 0.006 |
| Gender (%) | 0.855 | ||||
| Male | 131 (42.4) | 74 (43.8) | 49 (40.5) | 8 (42.1) | |
| Female | 178 (57.6) | 95 (56.2) | 72 (59.5) | 11 (57.9) | |
| Tumor location (%) | 0.526 | ||||
| Body and fundus | 169 (54.7) | 88 (52.1) | 69 (57.0) | 12 (63.2) | |
| Neck and duct | 140 (45.3) | 81 (47.9) | 52 (43.0) | 7 (36.8) | |
| Tumor differentiation (%) | 0.439 | ||||
| Well and moderate | 238 (77.0) | 133 (78.7) | 89 (73.6) | 16 (84.2) | |
| Poor | 71 (23.0) | 36 (21.3) | 32 (26.4) | 3 (15.8) | |
| AJCC staging, n | 0.000 | ||||
| II | 25 | 25 | 0 | 0 | |
| IIIA | 60 | 56 | 4 | 0 | |
| IIIB | 56 | 46 | 10 | 0 | |
| IVA | 70 | 42 | 28 | 0 | |
| IVB | 98 | 0 | 79 | 19 | |
| AJCC – American Joint Committee on Cancer; SD – standard deviation. | |||||